Journal
INDIAN JOURNAL OF CANCER
Volume 54, Issue -, Pages S55-S64Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/ijc.IJC_589_17
Keywords
Adverse events; epidermal growth factor receptor; nonsmall cell lung cancer; tyrosine kinase inhibitors
Categories
Ask authors/readers for more resources
The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of EGFR-mutant nonsmall cell lung cancer (NSCLC). These EGFR TKIs demonstrate a different adverse event (AE) profile as compared to conventional chemotherapy agents. They are more commonly associated with cutaneous AEs and diarrhea while hematological AEs occurred commonly with chemotherapy agents. These AEs are the extension of pharmacological effect and occur as a result of blockade of EGFR-regulated pathways in the skin and gastrointestinal tract. This review article sheds light on the safety profile of first-, second-, and third-generation EGFR TKIs based on data obtained from several clinical trials conducted in NSCLC patients and highlights trials comparing these agents with the conventional chemotherapy agents. The strategies to manage EGFR TKI-related AEs are also reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available